← Leaderboards
Paul Woolf
University Of Rochester
$34,404
Attributed
$34,404
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$34,404 · 3
By mechanism
M01$34,404 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- John E Gerich$2,977,172
- Richard C. Reichman$18,935,739
- Kathleen M Hoeger$827,011
- Roger M Kurlan$13,810,390
- Steven Wittlin$83,647
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical ResearchDrug Screening /EvaluationHuman SubjectCombination ChemotherapyDiabetes Mellitus TherapyHypoglycemic AgentsInsulinNoninsulin Dependent Diabetes MellitusTroglitazoneAntihyperlipoproteinemic AgentClinical Trial Phase IDrug Adverse EffectPharmacokineticsPolycystic Ovary SyndromeThiazolesAndrogens
Grant awards (6)
S&E OF TROGLITAZONE IN POLYCYSTIC OVARY SYNDROME$0
M01 · FY2002 · RR
OL EXTENSION ASSESS LTS,T &E OF BRL49653C ADMIN 2/DAY COMBIN W/ INSU$0
M01 · FY2002 · RR
26 WK STUDY TO EVALUATE SET WHEN BRL 49653C ADMINISTERED TO PATIENTS WITH NIDDM$19,613
M01 · FY2001 · RR
26 WK STUDY TO EVALUATE SET WHEN BRL 49653C ADMINISTERED TO PATIENTS WITH NIDDM$14,791
M01 · FY2000 · RR
S&E OF TROGLITAZONE IN POLYCYSTIC OVARY SYNDROME$0
M01 · FY2000 · RR
OL EXTENSION ASSESS LTS,T &E OF BRL49653C ADMIN 2/DAY COMBIN W/ INSU$0
M01 · FY2000 · RR